by The global HER-2 Negative Breast Cancer Market features a range of therapeutics that provide targeted treatment for breast cancer cells lacking the human epidermal growth factor receptor 2 (HER2). Chemotherapy still represents the most widely adopted therapeutic approach for HER-2 negative disease. However, the availability of novel targeted agents such as PARP inhibitors, CDK 4/6 inhibitors, PI3K inhibitors, and immune checkpoint inhibitors have significantly improved survival outcomes. The global HER-2 Negative Breast Cancer Market is estimated to be valued at US$ 15982.51 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the HER-2 Negative Breast Cancer Market is the rising focus on immunotherapy. Drugs targeting immune checkpoints like PD-1 and PD-L1 are demonstrating promising results in clinical trials for triple-negative breast cancer (TNBC), a subtype of HER-2 negative disease. Avelumab by Merck KGaA received FDA approval in 2020 for treating PD-L1 positive advanced TNBC. Several other immunotherapies are under investigation that could expand treatment options. Furthermore, combination strategies evaluating immunotherapy with chemotherapy, hormonal therapy or targeted agents hold potential to offer enhanced responses against tumor cells. This is expected to fuel the demand of immune checkpoint inhibitors in the coming years.
Porter’s Analysis
Threat of new entrants: The barrier to entry in the HER-2 negative breast cancer market is moderately high as extensive R&D is required for drug development. Complex clinical trials and regulatory approvals further increase investment requirements.
Bargaining power of buyers: The bargaining power of buyers is moderate. Despite a large patient pool, most drugs have few direct substitutes. Buyers have some leverage due to competition between available therapies.
Bargaining power of suppliers: Suppliers of active pharmaceutical ingredients and contract manufacturing organizations face moderate pressure due to the specialized nature of production. However, switching costs for custom manufacturing are moderately high.
Threat of new substitutes: The threat of substitutes is moderate given ongoing research into new classes of drugs and combination therapies. Immuno-oncology drugs are emerging as alternatives.
Competitive rivalry: Rivalry in the market is high due to major players investing heavily in innovative drug development and marketing. Fierce competition to gain market share exists.
Key Takeaways
The Global HER-2 Negative Breast Cancer Market Size is expected to witness high growth over the forecast period. North America currently dominates the market due to early drug adoption and significant research investments in the region. The high prevalence of breast cancer in the US and Canada, along with favorable reimbursement policies, drive market growth.
Asia Pacific is anticipated to be the fastest growing regional market owing to rising healthcare expenditure andgrowing diagnosis rates in China, India, and Japan. Improving accessibility to advanced treatment options will boost demand.
Key players operating in the HER-2 negative breast cancer market are Robert Bosch GmbH (Germany), HELLA KGaA (Germany), Continental AG (Germany), Denso Corporation (Japan), Delphi Automotive PLC (U.K.), Autoliv Inc. (Sweden), and Valeo S.A. (France). These companies mainly focus on developing novel targeted therapies and combination regimens to expand indications and gain higher market share.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
